Neuronetics Inc

Neuronetics, Inc. commercial stage medical technology company, which engages in the designing, developing and marketing products for the patients suffering from psychiatric disorders. It operates through United States and International geographical segments. The firm offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon, and Thomas D. Weldon in April 2003 and is headquartered in Malvern, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Neuronetics reports robust Q4 performance, eyes nurse practitioner opportunities

Neuronetics delivered a strong performance in Q4 2022, showcasing revenue growth, operational achievements, and strategic partnerships.
While facing challenges in managing losses and revenue fluctuations, the company is focused on key initiatives and opportunities for future growth.
By leveraging upcoming opportunities with nurse practitioners and addressing analyst inquiries, Neuronetics aims to navigate challenges and drive sustainable growth in 2023.

Neuronetics Inc reports revenue growth and strategic advancements in Q1 2023

Neuronetics Inc's Q1 2023 performance reflects revenue growth, operational advancements, and strategic initiatives aimed at driving market expansion and financial stability.
While facing challenges in gross margin decline and negative EBITDA, the company's focus on cost management, recovery from merger disruption, and revenue guidance raise position it for future success.
With opportunities in expanded patient access, market growth, and product enhancements, Neuronetics is poised to capitalize on its strengths and navigate challenges effectively in the coming quarters.

Neuronetics reports solid Q2 performance, eyes growth amidst challenges

Neuronetics demonstrated resilience and growth in Q2 2023, with revenue increases and strategic advancements in technology and policy.
While facing challenges from closures and relocations, the company remains focused on financial stability and operational efficiency.
Opportunities lie in new technology clearances, favorable policy changes, and the growing demand for TMS therapy education and services.
Overall, Neuronetics' performance, strengths, challenges, and opportunities position the company for continued growth and market impact.

Neuronetics Inc reports solid Q3 earnings, faces challenges in expenses

Neuronetics Inc (STIM) delivered a strong performance in Q3 2023, showcasing revenue growth and operational advancements.
While facing challenges in aligning revenue with operating expenses, the company maintains a solid financial position and pursues growth opportunities.
By focusing on enhancing patient care standards, expanding market reach, and optimizing financial performance, Neuronetics Inc aims to drive sustainable growth and value creation.

Neuronetics Inc posts record revenue in Q4 2023 earnings call

Neuronetics Inc delivered a strong Q4 performance with revenue growth and achieving positive cash flow for the first time. The company's focus on strategic initiatives, regulatory advancements, and revenue guidance for 2024 indicate a positive trajectory for growth and profitability.

Neuronetics Inc reports revenue growth and strategic partnerships in Q1

Neuronetics Inc's Q1 2024 performance reflects revenue growth, operational efficiency improvements, and a strong financial position.
Strengths include successful programs, strategic partnerships, and growth opportunities in new market segments.
Challenges in system sales and revenue collection highlight areas for improvement, while opportunities in market expansion and revenue growth are promising.
Overall, Neuronetics shows resilience, innovation, and a strategic focus on driving growth and improving patient outcomes.

Neuronetics Inc reports Q2 revenue decline, eyes growth opportunities

Neuronetics Inc faced revenue challenges due to a cybersecurity breach but showed resilience in key areas.
Strategic adjustments and positive program results indicate a focus on growth and market expansion.
Acquisition and new debt facility offer opportunities for future expansion and financial stability.

Neuronetics reports solid Q3 earnings, eyes profitability and growth

Neuronetics is focused on optimizing operations, profitability, and cash flow breakeven by Q3 2025.
Greenbrook acquisition approval and strong business position provide a foundation for future growth.
Challenges include managing treatment session weakness and debt levels while pursuing revenue growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Neuronetics, Inc. is a commercial stage medical technology company, which focuses on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders. It operates through United States and International geographical segments. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon, and Thomas D. Weldon in 1998 and is headquartered in Malvern, PA.

Lowest satisfaction among medication users, highest for users of non-drug solution TMS Therapy Lowest satisfaction among medication users, highest for users of non-drug solution TMS Therapy

New Depression Barometer Survey Shows Patients Are Stopping Treatment Due to Dissatisfaction

The Company is recognized for its commitment to employees' well-being The Company is recognized for its commitment to employees' well-being

Neuronetics Wins 2023 Bell Seal for Workplace Mental Health

Neuronetics, Inc. (NASDAQ:STIM ) Q1 2023 Earnings Conference Call May 13, 2023 8:30 AM ET Company Participants Mark Klausner - ICR Westwicke Keith Sullivan - President and Chief Executive Officer Steve Furlong - Chief Financial Officer Operator Thank you for standing by, and welcome to the Neuronetics First Quarter 2023 Financial and Operating Results. [Operator Instructions] As a reminder, today's program is being recorded.

Neuronetics, Inc. (STIM) Q1 2023 Earnings Call Transcript

MALVERN, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “company” or Neuronetics”) a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, that Keith Sullivan, President and Chief Executive Officer, and Steve Furlong, Senior Vice President, Chief Financial Officer, and Treasurer will present at the JMP Securities Life Sciences on Tuesday, May 16, 2023. The Company is scheduled to present at 12:30 pm Eastern Time the same day via webcast.

Neuronetics to Present at the JMP Securities Life Sciences Conference

MALVERN, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “company” or Neuronetics”) a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, today announced its financial and operating results for the first quarter of 2023.

Neuronetics Reports Record First Quarter 2023 Financial and Operating Results

Achievement demonstrates Company's commitment to rigorous standards for safe and effective products Achievement demonstrates Company's commitment to rigorous standards for safe and effective products

Neuronetics Receives MDSAP Certification and CE Mark Certification under New MDR

Data highlights the Company's commitment to advancing TMS and improving patient outcomes Data highlights the Company's commitment to advancing TMS and improving patient outcomes

Neuronetics Showcases New NeuroStar® TMS Findings at Clinical TMS Society Annual Meeting

Campaign features patients' experiences to support others with depression Campaign features patients' experiences to support others with depression

NeuroStar® Expands “Tap Into Possibility” Campaign in Honor of Mental Health Awareness Month

Strategic role strengthens NeuroStar® Advanced Therapy commercialization team Strategic role strengthens NeuroStar® Advanced Therapy commercialization team

Neuronetics Announces Lisa Metzner-Rosas as SVP, Chief Marketing Officer

MALVERN, Pa., April 28, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that United HealthCare has updated their Medicare Advantage policy in states covered by National Government Services (NGS) Medicare.

Neuronetics Announces Expanded TMS Access through United HealthCare

MALVERN, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it plans to release first quarter 2023 financial and operating results prior to market open on Tuesday, May 9th, 2023. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.

Neuronetics to Report First Quarter 2023 Financial and Operating Results and Host Conference Call

BlueCross BlueShield of Mississippi Latest to Allow Non-Physician Practitioners to Prescribe TMS BlueCross BlueShield of Mississippi Latest to Allow Non-Physician Practitioners to Prescribe TMS

Neuronetics Announces Continued Momentum for Expanded Health Insurance Coverage for TMS Therapy

Fifth FDA clearance in less than two years offers greater connectivity and flexibility to improve the patient and provider experience Fifth FDA clearance in less than two years offers greater connectivity and flexibility to improve the patient and provider experience

NeuroStar® Advanced Therapy Enhanced With Wi-Fi Capabilities

MALVERN, Pa., April 04, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, today provided a corporate update which includes entering into a new credit facility with investment affiliates managed by SLR Capital Partners, LLC (“SLR”) and providing Greenbrook TMS (“Greenbrook”) with a promissory note as part of an updated TMS device supply agreement.

Neuronetics Secures Up To $60 Million in New Debt Financing with SLR Capital Partners, Provides Greenbrook TMS with $6.0 Million Promissory Note

Fintel reports that Cannell Capital has filed a 13D/A form with the SEC disclosing ownership of 3.13MM shares of Neuronetics Inc (STIM).

Cannell Capital Now Owns 11.03% of Neuronetics

Award recognizes NeuroStar for its significant contributions toward patient wellbeing Award recognizes NeuroStar for its significant contributions toward patient wellbeing

NeuroStar® Advanced Therapy Receives Patient Impact Award from Life Sciences PA

Neuronetics, Inc. (NASDAQ:STIM ) Q4 2022 Earnings Conference Call March 7, 2023 8:30 AM ET Company Participants Mark Klausner - ICR Westwicke Keith Sullivan - President and Chief Executive Officer Steve Furlong - Chief Financial Officer Conference Call Participants Bill Plovanic - Canaccord Adam Maeder - Piper Sandler Margaret Kaczor - William Blair Daniel Stauder - JMP Securities Operator Good day and welcome to the Neuronetics Fourth Quarter and Full-Year 2022 Conference Call. At this time, all participants are in listen-only mode.

Neuronetics, Inc. (STIM) Q4 2022 Earnings Call Transcript

MALVERN, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, today announced its financial and operating results for the fourth quarter and full year of 2022.

Neuronetics Reports Record Fourth Quarter and Record Full Year 2022 Financial and Operating Results

United HealthCare Optum Reduces Barriers to TMS Eligibility for Depression Patients United HealthCare Optum Reduces Barriers to TMS Eligibility for Depression Patients

Neuronetics Announces TMS Coverage Criteria Changes for Over 23 Million Covered Lives

Company Launches a New Educational Campaign For Providers Company Launches a New Educational Campaign For Providers

Neuronetics Expands NeuroStar® Advanced Therapy's Proprietary TrakStar® Platform

MALVERN, Pa., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it plans to release fourth quarter 2022 financial and operating results prior to market open on Tuesday, March 7th, 2023. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.

Neuronetics to Report Fourth Quarter 2022 Financial and Operating Results and Host Conference Call

Poster Session Highlights the Strong Dose-Response Relationship and the Importance of Treating Beyond 30 Treatments With NeuroStar Advanced Therapy Poster Session Highlights the Strong Dose-Response Relationship and the Importance of Treating Beyond 30 Treatments With NeuroStar Advanced Therapy

Neuronetics Sponsors the 5th International Brain Stimulation Conference

Brainsway

I am bullish on the niche industry that uses magnetic stimulation for brain therapies. BrainsWay and Neuronetics are US-listed stocks in this niche, however they are highly unprofitable with volatile sales growth.

Why I Am Passing On BrainsWay And Neuronetics

New Senior Leadership Role Will Streamline Alignment of All Company Revenue-Generating Functions New Senior Leadership Role Will Streamline Alignment of All Company Revenue-Generating Functions

Neuronetics Announces Elevation of Sara Grubbs to SVP, Chief Revenue Officer

Today, we revisit a small medical device company called Neuronetics for the first time since January 2021. The stock is up some 30% over that time as Neuronetics has seen some notable milestones and delivered consistent sales growth.

News for Neuronetics Inc Stock (STIM)